Colorectal Cancer: Update Bulletin #2 [March 2018]
Gain new key opinion leader (KOL) insights on the latest events happening in the CRC treatment landscape
Topics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the Phase II CheckMate-142 trial evaluating Opdivo (nivolumab; Merck & Co.) and Yervoy (ipilimumab; BMS) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC.
How do KOLs perceive MVT-1075’s mechanism of action?
What are the experts’ views on targeting CA19-9 positive malignancies?
What concerns, if any, do KOLs have regarding MVT-1075?
How do KOLs view the NLR marker’s potential role in guiding clinical decisions related to Lonsurf?
What are the KOLs’ views on the Lonsurf safety and tolerability data in elderly patients?
How do KOLs perceive the potential of Lonsurf and oxaliplatin in combination?
What are the KOLs’ views on the new data presented from the CheckMate-142 trial?
Where in the treatment paradigm do KOLs believe the nivolumab plus ipilimumab combination should be used?
What concerns do KOLs raise about using nivolumab and ipilimumab in combination?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook